Trial 9L-22-5


A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis

Type: Treatment
Phase: Phase I/II
Status: Closed to Accrual with Ongoing Follow-up
Treatments: Other
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Casey O'Connell, M.D.
Other Trial Staff:  Christine Duran, Coordinator, Donna Fernando, Coordinator, Nelli Dimitrova, D.M., Hannah Trey, Coordinator, Sonny Tong, D.M., Brandon Sookdeo, D.M., Adrianne Harding, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.